CytomX Therapeutics's total assets for Q4 2025 were $152.50M, a decrease of -3.64% from the previous quarter. CTMX total liabilities were $52.56M for the fiscal quarter, a 3.33% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.